  The purposes of this article are to increase understanding of the concepts of theranostics and peptide receptor radionuclide therapy ( PRRT) as they apply to neuroendocrine tumors ( NETs); review the key 1 , 2 , and 3 clinical trial data leading to the approval of In January 2018 ,